Search results
7 hours ago · He has received research funds for clinical trials from: Juno Therapeutics, Celgene/BMS, Bristol-Myers Squibb, Precision Biosciences, Actinium Pharmaceuticals, Sanofi-Genzyme, Cargo Therapeutics ...
Jun 11, 2024 · On 30 May 2024, the US Food and Drug Administration (FDA) approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of systemic therapy, including a Bruton tyrosine kinase inhibitor (BTKi).
6 days ago · Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, today announced that it has received...
Jun 28, 2024 · JUNO Therapeutics is a biotech organization with a vision of growing an independent operation to revolutionize the field of immunotherapy and medical treatment.
Jun 17, 2024 · Key Takeaways. Acalabrutinib combined with BR reduced the risk of disease progression or death by 27% in older MCL patients. Median PFS was 66.4 months with acalabrutinib/BR versus 49.6 months with...
5 days ago · Juno Therapeutics is advancing a CAR T-cell therapy, which includes both CD4+ and CD8+ T-cells from the same patient, modified to express a BCMA-specific CAR.
Jun 17, 2024 · Two gene-editing therapies that deliver the CRISPR-edited autologous cell product exagamglogene autotemcel (Casgevy)—for the treatment of sickle-cell disease and transfusion-dependent β ...
